AstraZeneca Reiterates 80 Billion USD Revenue Target for 2030, Driven by Oncology Drugs Boosting Q2 Growth

Groonghui, July 27 — AstraZeneca reported Q2 revenue of $15.38 billion, with oncology business revenue increasing by 15% year-on-year, advancing towards its 2030 revenue target of $80 billion. The CEO expressed confidence in the R&D pipeline, stating that with the launch of new drugs such as Baxfendy and Etcamah, over half of the plan to launch 20 new drugs by 2030 has already been completed.